EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial

Lei Xu, Liyin Li, Qiutang Wang, Bing Pan, Leilei Zheng, Zheng Lin

Journal of Affective Disorders · 2024

DOI: 10.1016/j.jad.2024.05.063 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Lei Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Antidepressive Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Major Science and Technology Projects of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pharmacotherapy is one of the primary treatment modalities for depression. However, there is considerable variability in the individual response to antidepressant medications. Personalized medicine guided by pharmacogenomic testing may hold promise in addressing this issue. METHODS: In this study, 665 depressive patients were randomly enrolled into two groups: the pharmacogenomic testing group (n = 333) and the control group (n = 332). In the testing group, participants underwent pharmacogenomic testing, and clinicians customized the treatment plan with the result, while the control group relied solely on clinicians' experience. The primary outcomes were the proportion of remission and response, assessed with Hamilton Depression Rating Scale (HDRS). The secondary outcomes included changes in HDRS scores over time and frequency of adverse drug reactions by the participants. RESULTS: At week 8, the pharmacogenomic testing group showed significantly higher remission rates (24.0 % v.s. 15.1 %; RR = 1.117; P = 0.007) and response rates (39.3 % v.s. 25.7 %; RR = 1.225; P < 0.001) compared to the control group. By week 12, the pharmacogenomic testing group continued to demonstrate significant advantages in remission (31.0 % v.s. 20.0 %; RR = 1.159; P = 0.003) and response (48.7 % v.s. 37.3 %; RR = 1.224; P = 0.006). Additionally, adverse drug reactions were less frequent in the pharmacogenomic testing group. LIMITATIONS: This study is not blind to clinicians and it's a single-center study. CONCLUSIONS: Pharmacogenomic testing-guided drug therapy can provide greater assistance in the treatment of depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingAntidepressive AgentsHumansFemaleMaleAdultMiddle AgedMajor Depressive DisorderTreatment OutcomePsychiatric Status Rating ScalesPrecision MedicineDepressive DisorderRemission Induction

Stichwörter der Autor:innen

DepressionPharmacogenomicsPharmacotherapyPrecision medicinePsychiatric

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Department of Geriatric Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Psychiatry, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Psychiatry, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address: zll121@zju.edu.cn.
  • Department of Psychiatry, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address: 2194026@zju.edu.cn.

Förderung

  • National Major Science and Technology Projects of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Xu, L., Li, L., Wang, Q., Pan, B., Zheng, L., & Lin, Z. (2024). Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.05.063

Vancouver

Xu L, Li L, Wang Q, Pan B, Zheng L, Lin Z. Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.05.063

BibTeX
@article{Xu2024,
  author = {Xu, Lei and Li, Liyin and Wang, Qiutang and Pan, Bing and Zheng, Leilei and Lin, Zheng},
  title = {Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial},
  journal = {Journal of Affective Disorders},
  year = {2024},
  doi = {10.1016/j.jad.2024.05.063}
}
Kostenlos starten →